trk-130
Small moleculeexperimental
Clinical trial activity
0 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Mechanism of action
- Mu opioid receptorPARTIAL AGONIST
OPRM partial agonist
Centrally acting, selective for OPRM1 but also potent agonist at OPRD1 and OPRK1
Chemistry & pharmacology
Loading structure…
SMILES
O=C1c2ccccc2C(=O)N1[C@@H]1CC[C@@]2(O)C3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)C1O5- Mol. weight
- 472.54 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545408 ↗
Also known as
- n-(17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl)phthalimide
- naltalimide
- naltalimide
- naltalimide
- tak-363
- tak-363
- trk-130
- trk-130
- trk-130